Astellas Pharma’s recent $1.5B+ investment in an exclusive licensing agreement with Suzhou-based Evopoint Biosciences marks a significant strategic move in targeted cancer therapy. At the core of this agreement is the development of XNW27011, an early-stage Antibody Drug Conjugate (ADC) that targets the protein Claudin18.2, recognized as a potential marker for various malignancies. This antibody-drug […]